The transaction is expected to close in the third quarter of 2026.
If approved, Apnimed’s lead candidate oxnimbi would become the first pill to break onto the OSA market fraught with unmet needs.
BioMarin and n-Lorem will carry out preclinical studies and jointly select a lead candidate for trials.
Varun Sharma, founder and CEO of NEUVIOR, reflects on the necessitates of the recently forged India-UK pharma trade deal.
Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.
The combined formulation begins working in under 30 minutes and delivers pain relief for up to 12 hours.
